Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer

American Journal of Respiratory and Critical Care Medicine

Volumn 181, Issue 2, 2010, Pages 181-188

  Baty, Florent ^a   Facompré, Michaël ^b   Kaiser, Sergio ^c   Schumacher, Martin ^c   Pless, Miklos ^d   Bubendorf, Lukas ^e   Savic, Spasenija ^e   Marrer, Estelle ^c   Budach, Wolfgang ^c   Buess, Martin ^a   Kehren, Jeanne ^c   Tamm, Michael ^b   Brutsche, Martin H ^a  

^a Kantonsspital St Gallen ^*  (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Medical Oncology   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE; VASCULOTROPIN B; VEGFB PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRONCHOSCOPY; CLINICAL EVALUATION; CONTROLLED STUDY; DNA FINGERPRINTING; DNA MICROARRAY; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR CELL; VALIDITY; BIOPSY; CANCER STAGING; FEASIBILITY STUDY; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; LUNG; LUNG TUMOR; METAGENOMICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG; LUNG NEOPLASMS; MALE; METAGENOMICS; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

EID: 75649088160     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200812-1807OC     Document Type: Article

References (42)

1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
2. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
3. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
4. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98:13784-13789.
5. Beer DG, Kardia SLR, Huang C, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824.
6. Tsao M, Sakurada A, Cutz J, Zhu C, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353: 133-144.
7. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JMG, Macdonald J, Thomas D, Moskaluk C, Wang Y, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006;66:7466-7472.
8. Tomida S, Koshikawa K, Yatabe Y, Harano T, Ogura N, Mitsudomi T, Some M, Yanagisawa K, Takahashi T, Osada H, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene 2004;23:5360-5370.
9. Lu Y, Lemon W, Liu P, Yi Y, Morrison C, Yang P, Sun Z, Szoke J, Gerald WL, Watson M, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006;3:e467.
10. Chen H, Yu S, Chen C, Chang G, Chen C, Yuan A, Cheng C, Wang C, Terng H, Kao S, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
11. Shedden K, Taylor JMG, Enkemann SA, Tsao M, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multisite, blinded validation study. Nat Med 2008;14:822-827.
12. Guo NL, Wan Y, Tosun K, Lin H, Msiska Z, Flynn DC, Remick SC, Vallyathan V, Dowlati A, Shi X, et al. Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 2008;14:8213-8220.
13. Borczuk AC, Shah L, Pearson GDN, Walter KL, Wang L, Austin JHM, Friedman RA, Powell CA. Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 2004;170:167-174.
14. Virtanen C, Ishikawa Y, Honjoh D, Kimura M, Shimane M, Miyoshi T, Nomura H, Jones MH. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci USA 2002;99: 12357-12362.
15. Imperatori A, Harrison RN, Leitch DN, Rovera F, Lepore G, Dionigi G, Sutton P,DominioniL.Lung cancer inTeesside (UK) and Varese (Italy): a comparison of management and survival. Thorax 2006;61:232-239.
16. Spira A, Beane JE, Shah V, Steiling K, Liu G, Schembri F, Gilman S, Dumas Y, Calner P, Sebastiani P, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007;13:361-366.
17. British Thoracic Society Bronchoscopy Guidelines Committee. British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001;56 suppl 1:i1-21.
18. Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Figlin RA, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2008;6:228-269.
19. Marrer E, Baty F, Kehren J, Chibout S, Brutsche M. Past, present and future of gene expression-tailored therapy for lung cancer. Per Med 2006;3:165-175.
20. Baty F, Buess M, Kaiser S, Facompré M, Bubendorf L, Schumacher M, Budach W, Kehren J, Brutsche M. Prediction of major NSCLC tumor classes and clinical outcome by functional genomics of small bronchoscopic tumor biopsies: B7-03. J Thorac Oncol 2007;2:S355.
21. Neuschä fer D, Budach W, Wanke C, Chibout SD. Evanescent resonator chips: a universal platform with superior sensitivity for fluorescencebased microarrays. Biosens Bioelectron 2003;18:489-497.
22. Culhane AC, Perrière G, Considine EC, Cotter TG, Higgins DG. Between-group analysis of microarray data. Bioinformatics 2002;18: 1600-1608.
23. Baty F, Facompré M, Wiegand J, Schwager J, Brutsche MH. Analysis with respect to instrumental variables for the exploration of microarray data structures. BMC Bioinformatics 2006;7:422.
24. Trevino V, Falciani F. GALGO: an R package for multivariate variable selection using genetic algorithms. Bioinformatics 2006;22:1154-1156.
25. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004;2:E108.
26. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 2006;6:735-741.
27. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
28. Baty F, Bihl MP, Perrière G, Culhane AC, Brutsche MH. Optimized between-group classification: a new jackknife-based gene selection procedure for genome-wide expression data. BMC Bioinformatics 2005;6:239.
29. Proksch E, Fö lster-Holst R, Jensen J. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006;43: 159-169.
30. Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, Shibahara J, Taniguchi H, Ishikawa S, Ito H, Yamamoto S, et al. Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res 2005;11:1776-1785.
31. Zech VFE, Dlaska M, Tzankov A, Hilbe W. Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancer. Cancer Detect Prev 2006;30:395-402.
32. Hu R, Wu R, Deng J, Lau D. A small proline-rich protein, spr1: specific marker for squamous lung carcinoma. Lung Cancer 1998;20:25-30.
33. Nacht M, Dracheva T, Gao Y, Fujii T, Chen Y, Player A, Akmaev V, Cook B, Dufault M, Zhang M, et al. Molecular characteristics of nonsmall cell lung cancer. Proc Natl Acad Sci USA 2001;98:15203-15208.
34. Whang-Peng J, Knutsen T, Gazdar A, Steinberg SM, Oie H, Linnoila I, Mulshine J, Nau M, Minna JD. Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chromosomes Cancer 1991;3:168-188.
35. Khoor A, Whitsett JA, Stahlman MT, Halter SA. Expression of surfactant protein B precursor and surfactant protein B mRNA in adenocarcinoma of the lung. Mod Pathol 1997;10:62-67.
36. Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch 2002;440:353-361.
37. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-158.
38. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550.
39. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998;95:11709-11714.
40. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 2005;109:227-241.
41. Süer Gökmen S, Yö rük Y, Cakir E, Yorulmaz F, Gülen S. Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer Biochem Biophys 1999;17:125-131.
42. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J, Sotomayor EM, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-5849.